- Home
- RNAZ vs KPRX Comparison
RNAZ vs KPRX Comparison
Compare RNAZ & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- KPRX
- Stock Information
- Founded
- RNAZ 2016
- KPRX 1998
- Country
- RNAZ United States
- KPRX United States
- Employees
- RNAZ N/A
- KPRX N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RNAZ Health Care
- KPRX Health Care
- Exchange
- RNAZ Nasdaq
- KPRX Nasdaq
- Market Cap
- RNAZ 8.7M
- KPRX 9.2M
- IPO Year
- RNAZ 2021
- KPRX N/A
- Fundamental
- Price
- RNAZ $15.00
- KPRX $2.80
- Analyst Decision
- RNAZ Strong Buy
- KPRX Strong Buy
- Analyst Count
- RNAZ 1
- KPRX 1
- Target Price
- RNAZ $280.00
- KPRX $10.00
- AVG Volume (30 Days)
- RNAZ 13.8K
- KPRX 35.6K
- Earning Date
- RNAZ 11-13-2025
- KPRX 11-07-2025
- Dividend Yield
- RNAZ N/A
- KPRX N/A
- EPS Growth
- RNAZ N/A
- KPRX N/A
- EPS
- RNAZ N/A
- KPRX N/A
- Revenue
- RNAZ N/A
- KPRX N/A
- Revenue This Year
- RNAZ N/A
- KPRX N/A
- Revenue Next Year
- RNAZ N/A
- KPRX N/A
- P/E Ratio
- RNAZ N/A
- KPRX N/A
- Revenue Growth
- RNAZ N/A
- KPRX N/A
- 52 Week Low
- RNAZ $6.15
- KPRX $2.25
- 52 Week High
- RNAZ $739.20
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- RNAZ 84.37
- KPRX 59.99
- Support Level
- RNAZ $10.32
- KPRX $2.67
- Resistance Level
- RNAZ $12.28
- KPRX $2.89
- Average True Range (ATR)
- RNAZ 0.87
- KPRX 0.12
- MACD
- RNAZ 0.57
- KPRX 0.02
- Stochastic Oscillator
- RNAZ 91.34
- KPRX 79.32
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.